Med-IQ CME: Updates in R/M HNSCC From ESMO25: Novel Targeted Agents and Immunotherapies
In this MedX activity, Robert Haddad, MD, explores the latest clinical data for emerging novel therapies for recurrent/metastatic head and neck squamous cell carcinoma with an emphasis on results presented at ESMO 2025.
Cost: Free
View Offer chevron_rightKey Features
Explore the latest data on emerging novel therapies for R/M HNSCC.
Topics Covered
Emerging novel therapies for R/M HNSCC
Learning Objectives
1. Explain the mechanisms of action of novel therapies for R/M HNSCC
2. Integrate emerging clinical trial data surrounding novel agents for the treatment of R/M HNSCC into cases representing patients in practice
Target Audience
This activity is intended for medical oncologists, radiation oncologists, and otolaryngologists.
Additional credit info
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.